Mundiña-Weilenmann Cecilia, Said Matilde, Vittone Leticia, Ferrero Paola, Mattiazzi Alicia
Centro de Investigaciones Cardiovasculares, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Argentina.
Mol Cell Biochem. 2003 Oct;252(1-2):239-46. doi: 10.1023/a:1025504709518.
The status of phospholamban (PLB) phosphorylation in the ischemia-reperfused hearts remains controversial. Although a decrease in the phosphorylation of both PLB residues (Ser16, PKA site, and Thr17, CaMKII site) was previously reported, experiments from our laboratory failed to detect this decrease. In an attempt to elucidate the cause for this discrepancy, experiments were performed in Langendorff-perfused rat hearts with two main goals: (1) To determine whether keeping pacing during ischemia, a protocol followed in other ischemia-reperfusion models, decreases the phosphorylation of PLB residues, below pre-ischemic values; (2) To investigate whether a maximal beta-adrenergic challenge allows to detect a decrease in the ability of PLB to be phosphorylated in ischemia-reperfused hearts. Hearts were submitted to a global ischemia/reperfusion protocol (20/30 min) with (P) or without (NP) pacing during ischemia, and phosphorylation of PLB residues was assessed by immunodetection. The recovery of contractility upon reperfusion was lower in P vs. NP hearts. Ser16 of PLB, was phosphorylated at the end of ischemia in NP hearts. This increase appeared earlier in P hearts and was significantly diminished by catecholamine depletion and beta-blockade. Thr17 site was phosphorylated at the beginning of ischemia and the onset of reperfusion. The ischemia-induced phosphorylation of Thr17 was higher and more sustained in P vs. NP hearts, and inhibited by the calcium channel blocker, nifedipine, whereas the reperfusion-induced increase in Thr17 phosphorylation was similar in P and NP hearts and was significantly diminished by the Na+/Ca2+ exchanger inhibitor KB-R7943. Phosphorylation of PLB residues did not decrease below basal levels at any time during ischemia and reperfusion. However, the phosphorylation, inotropic and lusitropic response to beta-adrenergic stimulation was significantly decreased both in P and NP hearts.
缺血再灌注心脏中磷酸化受磷蛋白(PLB)的状态仍存在争议。尽管先前有报道称PLB的两个残基(丝氨酸16,蛋白激酶A作用位点;苏氨酸17,钙/钙调蛋白依赖性蛋白激酶II作用位点)的磷酸化水平降低,但我们实验室的实验未能检测到这种降低。为了阐明这种差异的原因,在Langendorff灌注的大鼠心脏上进行了实验,主要有两个目标:(1)确定在缺血期间保持起搏(其他缺血再灌注模型采用的方案)是否会使PLB残基的磷酸化水平降至缺血前水平以下;(2)研究最大程度的β-肾上腺素能刺激是否能检测到缺血再灌注心脏中PLB磷酸化能力的降低。心脏接受全心缺血/再灌注方案(20/30分钟),缺血期间有(P组)或无(NP组)起搏,通过免疫检测评估PLB残基的磷酸化情况。再灌注时,P组心脏的收缩功能恢复低于NP组。NP组心脏在缺血末期PLB的丝氨酸16发生磷酸化。这种增加在P组心脏中出现得更早,并且通过儿茶酚胺耗竭和β受体阻滞剂可使其显著降低。苏氨酸17位点在缺血开始时和再灌注开始时发生磷酸化。与NP组心脏相比,缺血诱导的苏氨酸17磷酸化在P组心脏中更高且更持久,并被钙通道阻滞剂硝苯地平抑制,而再灌注诱导的苏氨酸17磷酸化增加在P组和NP组心脏中相似,并被钠/钙交换体抑制剂KB-R7943显著降低。在缺血和再灌注的任何时候,PLB残基的磷酸化水平均未降至基础水平以下。然而,P组和NP组心脏对β-肾上腺素能刺激的磷酸化、变力性和变时性反应均显著降低。